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BACKGROUND: The burden of noncommunicable diseases and their risk factors 
has rapidly increased worldwide, including in India. Innovative management 
strategies with electronic decision support and task sharing have been assessed 
for hypertension, diabetes mellitus, and depression individually, but an 
integrated package for multiple chronic condition management in primary care 
has not been evaluated.
METHODS: In a prospective, multicenter, open-label, cluster-randomized controlled 
trial involving 40 community health centers, using hypertension and diabetes 
mellitus as entry points, we evaluated the effectiveness of mWellcare, an mHealth 
system consisting of electronic health record storage and an electronic decision 
support for the integrated management of 5 chronic conditions (hypertension, 
diabetes mellitus, current tobacco and alcohol use, and depression) versus enhanced 
usual care among patients with hypertension and diabetes mellitus in India. At 
trial end (12-month follow-up), using intention-to-treat analysis, we examined the 
mean difference between arms in change in systolic blood pressure and glycated 
hemoglobin as primary outcomes and fasting blood glucose, total cholesterol, 
predicted 10-year risk of cardiovascular disease, depression score, and proportions 
reporting tobacco and alcohol use as secondary outcomes. Mixed-effects regression 
models were used to account for clustering and other confounding variables.
RESULTS: Among 3698 enrolled participants across 40 clusters (mean age, 
55.1 years; SD, 11 years; 55.2% men), 3324 completed the trial. There was no 
evidence of difference between the 2 arms for systolic blood pressure (∆=−0.98; 
95% CI, −4.64 to 2.67) and glycated hemoglobin (∆=0.11; 95% CI, 
−0.24 to 0.45) even after adjustment of several key variables (adjusted 
differences for systolic blood pressure: – 0.31 [95% CI, −3.91 to 3.29]; for 
glycated hemoglobin: 0.08 [95% CI, −0.27 to 0.44]). The mean within-
group changes in systolic blood pressure in mWellcare and enhanced 
usual care were −13.65 mm Hg versus −12.66 mm Hg, respectively, 
and for glycated hemoglobin were −0.48% and −0.58%, respectively. 
Similarly, there were no differences in the changes between the 2 groups 
for tobacco and alcohol use or other secondary outcomes.
CONCLUSIONS: We did not find an incremental benefit of mWellcare over 
enhanced usual care in the management of the chronic conditions studied.
CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique 
identifier: NCT02480062.
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The burden of noncommunicable diseases (NCDs), including mental health conditions, and their as-sociated risk factors has rapidly increased world-
wide, including in India.1,2 A recent estimate suggests 
a US $2.32 trillion loss in national income in India be-
tween 2012 and 2030 resulting from cardiovascular 
disease (CVD) and diabetes mellitus.3 The rapid rise in 
chronic disease burden, population aging, severe short-
age of skilled healthcare providers, and inadequately 
developed health systems together impose huge con-
straints on healthcare services in India.4
To better tackle the growing burden of chronic con-
ditions and their risk factors, the 1978 Alma Ata dec-
laration endorsed strengthening primary care to im-
prove health outcomes and the equitable distribution of 
healthcare services at low cost in the population.5 Bar-
riers that accentuate evidence to practice gaps include 
patient-level factors (low levels of awareness, low ad-
herence to medications and healthy lifestyle), physician-
level factors (limited time, clinical inertia), and system-
level factors (inadequately trained workforce, lack of 
health record keeping, lack of access to affordable ge-
neric medicines).6–9 Innovations at the primary care level 
with the use of mobile phone technologies and task 
sharing by trained nurses can empower, encourage, and 
facilitate care processes as well as strengthen healthcare 
delivery systems by overcoming these barriers.10,11
Systematic reviews and meta-analyses of studies 
evaluating the role of an electronic decision support 
(EDS) system for the management of chronic conditions 
show a paucity of well-designed studies on patient out-
comes.12,13 Furthermore, previous studies were either pi-
lot studies or studies that evaluated the effectiveness of 
EDS and nonphysician healthcare providers in managing 
single disease conditions (hypertension or diabetes mel-
litus).14–16 To the best of our knowledge, an integrated 
mHealth-based EDS system addressing multiple chronic 
conditions (hypertension, diabetes mellitus, depression, 
tobacco and alcohol use) collectively remains untested 
in India. Therefore, using hypertension and diabetes 
mellitus as entry points, we evaluated the effectiveness 
of a nurse-facilitated, mHealth-based EDS for the inte-
grated management of 5 chronic conditions in primary 
care settings of India through the mWellcare trial.
METHODS
The data, analytical methods, and study materials will be 
made available on request to other researchers for purposes 
of reproducing the results or replicating the procedure. Data 
will be available at Public Health Foundation of India’s Central 
Research Data Repository 6 months after completion of the 
study (July 2019).17
Study Design
The mWellcare trial was a pragmatic, open-label, cluster-ran-
domized controlled clinical trial in which community health 
centers (CHCs) were randomized to receive the mHealth-based 
EDS or enhanced usual care (EUC). We recruited eligible con-
senting participants with a confirmed diagnosis of hyperten-
sion or diabetes mellitus from 40 CHCs between April 5 and 
August 21, 2016. The last date of follow-up was September 
30, 2017. The trial methods have been previously published.18 
This study received ethics committee approval from the Public 
Health Foundation of India and London School of Hygiene 
and Tropical Medicine. The study was also cleared by the 
Indian Health Ministry Screening Committee. All participants 
provided written informed consent to participate. The study 
was conducted according to the study protocol (Method 1 in 
the online-only Data Supplement) and analyzed according to 
the statistical analysis plan (Method 2 in the online-only).
Study Setting and Participants
We recruited 20 CHCs each in Haryana (North India) and 
Karnataka (South India) for the trial. A CHC caters to a rural 
population of ≈80 000 to 120 000 and serves as a referral center 
for 4 primary health centers in the public healthcare delivery 
system.19 We selected the CHCs from 4 districts in Haryana and 
2 districts in Karnataka that were covered under the National 
Clinical Perspective
What Is New?
• This trial demonstrated that mWellcare, an mHealth 
system consisting of a clinical decision support sys-
tem and storage of electronic health records, com-
bined with enhanced usual care led to a reduction 
in systolic blood pressure and glycohemoglobin 
that was not significantly different from enhanced 
usual care alone in patients with hypertension and 
diabetes mellitus in primary care settings.
• The participants in the mWellcare arm also did not 
differ significantly on the secondary outcomes of 
fasting blood glucose, total cholesterol, predicted 
10-year risk of cardiovascular diseases, depression 
score, or proportions reporting tobacco and alco-
hol use; however, the mWellcare arm had higher 
self-reported adherence to medications.
What Are the Clinical Implications?
• This trial demonstrates the feasibility of an ambi-
tious multifactorial electronic health record– and 
electronic decision support–based mHealth inter-
vention across multiple sites at the primary care 
level using available trained staff.
• The overall null result, likely resulting from benefits 
achieved in the enhanced usual care arm, empha-
sizes the potential value of leveraging nonphysi-
cian providers and improving access to needed 
medications.
• National health policymakers in low- and middle-
income countries, including India, can use this 
information to inform decisions surrounding the 
rollout of widespread public health interventions.
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Program for the Prevention and Control of Cancer, Diabetes, 
Cardiovascular Diseases, and Stroke (NPCDCS). The NPCDCS, 
launched in 2008 in select districts, is a governmental program 
that focuses on the prevention and control of major NCDs 
through health promotion, early diagnosis, management, and 
referral of cases, strengthening infrastructure and capacity build-
ing.20 Under the NPCDCS, an NCD nurse was recommended to 
be used for the management of patients at the outpatient NCD 
clinic in each CHC. Of 40 selected CHCs, NCD nurses appointed 
under NPCDCS were available in only 10 CHCs in Karnataka 
before this study. Therefore, NCD nurses supported from trial 
funds were appointed at the remaining 30 selected CHCs.
Participants were eligible if they were ≥30 years of age, 
intended to reside in the catchment area of CHCs for ≥1 
year, and had been diagnosed with hypertension with systolic 
blood pressure (SBP) ≥140 mm Hg or diastolic blood pressure 
≥90 mm Hg or type 2 diabetes mellitus with fasting blood 
glucose ≥140 mg/dL or postprandial blood glucose ≥200 mg/
dL. Pregnant women, patients with type 1 diabetes mellitus, 
patients requiring immediate referral to tertiary care because 
of accelerated hypertension or diabetic complications, 
patients with learning difficulties or vision or hearing impair-
ments, and patients with malignancy or other life-threatening 
conditions were excluded from the study.
Randomization, Treatment Assignments, 
and Blinding
The CHC served as the unit of randomization. An independent 
biostatistician performed central computer-based randomiza-
tion of CHCs stratified by states (Haryana and Karnataka) and 
within each state by the availability of NCD nurses recruited 
under NPCDCS. Given the nature of the cluster-randomized 
trial design, neither personnel nor participants were blinded 
to the intervention. Assessments at study end were carried out 
by independent outcome assessors. The study biostatistician 
remained blinded throughout the study until the database 
was locked, at which point the study was fully unblinded.
Intervention
The intervention was developed by adapting existing clinical 
management guidelines to the local context, development, 
and validation of clinical algorithms and pilot testing of the 
mWellcare system.21–26 The mWellcare system was an Android 
application built on the CommCare platform. Details of the 
mWellcare system, platform, and its development and test-
ing are published elsewhere.27 Briefly, the mWellcare system 
was designed to generate EDS recommendations for the 
management of hypertension and diabetes mellitus, comor-
bid depression, and alcohol and tobacco use, tailored to the 
participant’s profile and risk level. It stored the health records 
electronically, enabling long-term monitoring and follow-up. 
It was also equipped to send short message service reminders 
(to take medication and attend follow-up visits) to patients.
In the intervention group (mWellcare arm), we provided 
centralized training on the current clinical management 
guidelines to all physicians. In addition, onsite training for ori-
entation to the mWellcare system was conducted at each site. 
For NCD nurses, we provided training in the management of 
hypertension, diabetes mellitus, depression, and tobacco and 
alcohol use. In addition, 3 days of training were provided 
to nurses on using the mWellcare system. This training was 
supplemented by another 2 days of onsite supervision and 
support. In all mWellcare arm sites, simplified charts on the 
management of these conditions were displayed prominently.
In the mWellcare arm, the NCD nurse used a tablet com-
puter installed with the mWellcare system to collect data on 
patient history, blood pressure, blood glucose, depression, 
tobacco and alcohol use, and current medications. From 
this patient-specific clinical information, the mWellcare sys-
tem generated a decision support recommendation (DSR) for 
the physician. The DSR printout summarized information on 
patient profile, diagnosed condition, comorbid conditions, 
and previous and current medications and recommended a 
treatment plan for the 5 chronic conditions based on stan-
dard guidelines (Figures I and II in the online-only Data 
Supplement). The DSR also provided a lifestyle modification 
advisory and date for the next follow-up visit. After review-
ing the DSR, the physician either agreed with the recom-
mendations or suggested changes in the treatment plan that 
were recorded in the mWellcare system by the NCD nurse. 
Next, the physician referred the patient to the NCD nurse, 
who provided lifestyle advice using the prompts of the DSR. 
In addition, the nurse provided pamphlets (in the local lan-
guage) to each participant. Participants were followed up for 
12 months. At every scheduled follow-up visit, the patients’ 
clinical parameters were recorded to generate a longitudinal 
trend/summary by the mWellcare system. In addition, partici-
pants received short message service reminders for scheduled 
follow-up visits and medication adherence. Each mWellcare 
site received a monthly report on the number of partici-
pants reporting for the scheduled follow-up and the average 
change in clinical parameters at the CHC level.
Enhanced Usual Care
In the EUC alone arm, we provided training to physicians on 
the clinical management guidelines for hypertension and dia-
betes mellitus. In addition, as with the mWellcare arm, charts 
on the management of these conditions were displayed prom-
inently at the outpatient clinics. We also conducted the NCD 
nurses’ training in the management of hypertension and dia-
betes mellitus. To balance both study arms, we provided the 
EUC NCD nurses with a tablet computer (without the mWell-
care system) for collecting data at the baseline visit. Physicians 
in the EUC arm managed their patients with the assistance of 
NCD nurses, according to their clinical judgment. In addition, 
the EUC arm NCD nurses provided and explained the lifestyle 
advice pamphlet (in local languages, Hindi and Kannada) to 
each participant. Follow-up in the EUC arm was at the discre-
tion of the treating physicians.
Outcomes
The primary study outcomes were the between-group differ-
ences in mean change (from baseline to 1 year) in SBP and 
glycated hemoglobin (HbA1c) among participants with hyper-
tension and diabetes mellitus, respectively. The secondary 
outcomes included the between-group difference in mean 
change (from baseline to 1 year) in fasting plasma glucose, 
total cholesterol, predicted 10-year risk of CVD with the 
recalibrated Framingham risk score, tobacco use, body mass 
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index, and alcohol use. Depression score was measured only 
at the end-of-study evaluation. The Framingham Risk Score 
was recalibrated to the Indian population with the methodol-
ogy suggested by Chow et al.28 To generate the values for 
recalibration, we used World Health Organization data on 
yearly estimates of CVD mortality in India (2012) and the 
average values of risk factors in the CARRS study (Centre for 
Cardiometabolic Risk Reduction in South Asia).29
Data Collection
Blood pressure was measured with automated blood pressure 
monitors (Omron HEM 907), height was measured with a sta-
diometer (Seca 213), and weight was measured with a digital 
weighing machine (Seca 813). Blood samples for HbA1c and 
total cholesterol were analyzed at laboratories that had accredi-
tation from the National Accreditation Board for Testing and 
Calibration Laboratories. Capillary blood was used to measure 
fasting blood glucose with a glucometer. Information about 
tobacco use and physical activity (with the modified CARRS 
questionnaire) was obtained in both arms.29 Depression was 
diagnosed with the Patient Health Questionnaire-9, and alco-
hol consumption (with the Alcohol Use Disorder Identification 
Test) was assessed only in the mWellcare arm.30,31 At the end-of-
study assessment, the Alcohol Use Disorder Identification Test 
questionnaire and Patient Health Questionnaire-9 were used to 
measure alcohol use and depression, respectively, in both arms.
We conducted a rigorous process evaluation in the trial. 
Trained research staff using a structured observation checklist 
conducted periodic monitoring visits of trial sites to assess the 
fidelity of the intervention. Information on contextual factors 
such as the availability of common antihypertensive drugs, 
antihyperglycemic drugs, statin, and aspirin was collected 
from each CHC every fortnight by the research staff. Data 
on follow-up visits and agreement of physicians with the DSR 
were obtained from the mWellcare system server database. 
At study end, participants reported adherence to medications 
in the week before the clinic visit (values ranging from 0–7 
days) and perceived quality of care (medicine availability, guid-
ance from the physician, quality of care, frequency of blood 
pressure measurement, and care provided by the NCD nurse). 
We also conducted in-depth interviews with patients, NCD 
nurses, and physicians at the end of the trial to obtain infor-
mation on perceived barriers and facilitators that influenced 
the uptake of the intervention.
Sample Size
This study was powered for the primary outcomes of 
between-group difference in mean change in SBP and HbA1c 
from baseline to 1 year. Sample size calculation was based 
on the assumption that recruitment of 40 participants with 
hypertension per cluster in 40 clusters would yield >98% 
power to detect a true mean difference of 4 mm Hg in the ∆ 
change in SBP between the mWellcare and EUC arms, assum-
ing a 15 mm Hg SD of the change in both arms with a type I 
error of 5% and an intraclass correlation of 0.05.15 Similarly, 
40 participants with diabetes mellitus per cluster would yield 
a power >99% for detecting a true difference in the average 
change of HbA1c between the 2 arms of 0.37%, assuming 
a 1.1% SD of the changes in both arms and an intraclass 
correlation of 0.04.29,32 To adhere to the previous statistical 
power and assuming a 20% loss to follow-up, we proposed 
enrolling 3600 participants, that is, 90 participants at each of 
the 40 CHCs selected in the trial. All calculations were based 
on the formula for the comparison of 2 means in cluster-ran-
domized trials proposed by Hayes and Bennett.33
Statistical Analysis
The primary analyses followed the intention-to-treat princi-
ple. We analyzed each continuous outcome separately with 
Figure 1. CONSORT (Consolidated Standards 
for Reporting Trials) flow diagram. 
CHC indicates community health center; and 
EUC, enhanced usual care.
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a linear mixed model in which the dependent variable was 
the difference in the outcome (after minus before), and the 
main explanatory variable was the trial arm. We included 
a random effect of the CHC to account for the clustered 
design. Each model was adjusted by baseline outcome val-
ues in 2 ways: the patient’s regression to the mean effect 
was controlled by including the distance to the CHC mean 
of the patient’s baseline outcome value, and the baseline 
outcome means of the CHC was included to  control for 
baseline differences between CHCs.
The secondary outcomes that were dichotomous (tobacco 
and alcohol use) were analyzed at the CHC level as a change in 
the proportion of positive responses adjusted by baseline pro-
portions. We estimated adjusted and unadjusted models on 
the basis of logistic regressions weighted by CHC sample size.
In the adjusted models for each outcome (primary or sec-
ondary), we first examined the effect of each potential con-
founder by controlling for it separately, and only those that 
had a value of P>0.1 and caused a change in the trial effect 
by >10% were included in a multivariable-adjusted model. 
Each outcome variable was adjusted by a different set of 
potential confounders.
For the 2 main outcomes (SBP and HbA
1c), we performed 
a sensitivity analysis of the adjusted models with multiple 
imputations of missing data (Table I in the online-only Data 
Supplement). We imputed 5 data sets and calculated the 
mean effect using the Rubin rules. In the imputation equa-
tions, we included all baseline variables that had an asso-
ciation with the probability of missing in the outcome with 
a value of P<0.1 and did not have >40% missing data to 
improve outcome imputation. The substantive model, how-
ever, included only the same variables as the adjusted model 
without multiple imputations.
Subgroup analysis of the 2 main outcomes in each of the 
candidate variables (z) was done as a 2-step process. We first 
reestimated the unadjusted trial effect in the outcome (as in 
the main trial analysis) stratified by z, obtaining a separate 
effect (and standard error) in each stratum of z. We then did 
a meta-analysis of these effects across strata and computed 
the Q statistic for heterogeneity and its P value. This way of 
Table 1. Baseline Characteristics of Study Participants by Treatment Arm
Baseline Characteristics EUC Arm (n=1856)
mWellcare Arm 
(n=1842) SMD
Participants with hypertension, n (%) 932 (50.2) 906 (49.2) −0.021
Participants with diabetes mellitus, n (%) 625 (33.7) 683 (37.1) 0.071
Participants with both conditions, n (%) 299 (16.1) 253 (13.7) −0.067
Age, mean (SD), y 54.5 (10.9) 55.8 (11.0) 0.086
Male, n (%) 985 (53.1) 1056 (57.3) 0.159
Illiterate, n (%) 635 (34.5) 772 (41.9) −0.056
Primary education, n (%) 374 (20.3) 331 (18.0) −0.112
Secondary education and above, n (%) 847 (45.6) 739 (40.1) −0.358
Employed, n (%) 647 (34.9) 354 (19.2) −0.052
Previous ischemic heart disease, n (%) 66 (3.6) 49 (2.7) −0.274
Previous peripheral vascular disease, n (%) 81 (4.4) 5 (0.3) −0.003
Previous stroke, n (%) 33 (1.8) 32 (1.7) −0.174
Previous cardiovascular disease, n (%)* 161 (8.7) 81 (4.4) −0.219
Current tobacco user, n (%) 325 (17.5) 184 (10.0) −0.152
Current alcohol user, n (%) 229 (12.3) 143 (7.8) 0.222
Physically inactive, n (%) 743 (40.0) 1113 (60.4) 0.122
Height, mean (SD), cm 159.0 (9.3) 157.7 (9.1) −0.137
Weight, mean (SD), kg 65.4 (12.3) 64.6 (13.1) −0.059
Body mass index, mean (SD), kg/m2 25.8 (4.6) 26.0 (4.7) 0.031
SBP, mean (SD), mm Hg† 157.0 (16.3) 152.5 (14.7) −0.238
Diastolic blood pressure, mean (SD), mm Hg† 93.3 (10.0) 88.8 (10.8) −0.331
Fasting blood glucose, mean (SD), mg/dL‡§ 197.7 (67.0) 185.9 (60.5) −0.21
HbA1c, mean (SD), %‡ 9.3 (2.4) 9.5 (2.2) 0.049
Total cholesterol, mean (SD), mg/dL 191.8 (44.8) 194.5 (45.0) 0.061
CVD risk score, mean (SD), % 41.0 (21.9) 38.5 (20.2) −0.120
CVD indicates cardiovascular disease; EUC, enhanced usual care; HbA1c, glycated hemoglobin; SBP, systolic blood 
pressure; and SMD, standardized mean difference.
*Previous ischemic heart disease, peripheral vascular disease, and stroke combined.
†Participants with hypertension, n=2390 (EUC arm, 1231; mWellcare arm, 1159).
‡Participants with diabetes mellitus, n=1860 (EUC arm, 924; mWellcare arm, 936).
§Using capillary blood.
D
ow
nloaded from
 http://ahajournals.org by on March 9, 2019
Prabhakaran et al mHealth for Chronic Conditions in India
Circulation. 2019;139:380–391. DOI: 10.1161/CIRCULATIONAHA.118.038192 January 15, 2019 385
ORIGINAL RESEARCH 
ARTICLE
studying interactions allows a separate model per stratum 
and does not need to force the same regression to the mean 
effect or random-effects distribution in all strata.
RESULTS
Of the 4270 participants screened, 4056 met study eli-
gibility criteria, and 3698 (EUC arm, 1856; mWellcare 
arm, 1842) were enrolled in the trial. Nearly 90% of 
the participants (n=3324) completed the end-of-study 
assessment at 12 months of enrollment (Figure 1).
Baseline Characteristics
Overall, at baseline, participants’ mean age was 
55.1±11.0 years, 55.2% were male, 42.9% had higher 
than primary school education, and 27.1% were em-
ployed. Table  1 shows baseline characteristics of par-
ticipants by each arm. The EUC arm had a higher pro-
portion of participants with secondary education and 
above (45.6% versus 40.1%), employment (34.9% 
versus 19.2%), peripheral vascular disease (4.4% versus 
0.3%), self-reported tobacco use (17.5% versus 10.0%) 
and alcohol use (12.3% versus 7.8%), and higher mean 
SBP (157.0 mm Hg versus 152.5 mm Hg). Other baseline 
characteristics between the 2 arms were similar.
Primary and Secondary Outcomes
Of the 3698 participants, 3324 (89.9%) completed 
the study assessment. We observed a significant de-
cline in SBP from baseline to study end in each arm 
(EUC, −12.7 mm Hg; mWellcare, −13.7 mm Hg). 
Similarly, a significant decline in HbA1c at 1 year 
was observed in both arms (EUC, −0.58%; mWell-
care, −0.48%). However, we found no difference in 
change in SBP between the 2 arms (−1.0; 95% CI, 
−4.6 to 2.7), which were similar after adjustments 
(−0.3; 95% CI, −3.9 to 3.3). Similarly, there was no 
difference in the change in HbA1c between the 2 arms 
(unadjusted, 0.11 [95% CI, −0.24 to 0.45]; after ad-
justments, 0.08 [95% CI, −0.27 to 0.44]). Table  2 
gives the participants’ characteristics at study end in 
the 2 arms, and Table 3 shows the difference in mean 
change from baseline to 1 year in the primary and 
secondary outcomes between the 2 arms, both un-
adjusted and adjusted for cluster and other variables 
that influenced the outcome measures.
The sensitivity analysis performed by imputing miss-
ing values for outcome variables revealed similar results 
(Table II in the online-only Data Supplement). The ob-
served intraclass correlation coefficient in the data for 
the change of SBP was marginally higher than what we 
assumed for sample size calculation (assumed, 5% ver-
sus observed, 6%) but much lower for the change of 
HbA
1c (assumed, 4% versus observed, 2%). However, 
the power for the SBP analysis remained >97% with 
the current sample size.
There were no differences in secondary outcomes: 
fasting blood glucose, total cholesterol, predicted 10-
year risk of CVD, body mass index, and tobacco and 
alcohol use. The difference in the mean score for al-
cohol use and the mean depression score, which was 
assessed only at the end of the trial, did not differ be-
tween the 2 arms.
Subgroup Analysis
Figures 2 and 3 depict results of subgroup analyses for 
the primary outcomes of SBP and HbA1c, respectively, 
by state (Haryana and Karnataka), type of appointment 
of NCD nurse (trial fund supported versus NPCDCS sup-
ported), stage of hypertension (stage 1 versus 2), and 
metabolic profile at baseline, age, sex, education, and 
alcohol use. We did not observe any heterogeneity in 
the differences between the 2 arms.
Process Outcomes
Among key process indicators, adherence to medica-
tion (during the last 7 days) by participants showed a 
significant difference between arms (Table 4). Com-
pared with the EUC arm, patients in the mWellcare 
arm reported greater adherence to antihypertensive 
Table 2. End-of-Study Characteristics of Study Participants by 
Treatment Arm
Characteristics EUC Arm
mWellcare 
Arm
Participants with baseline and end-of-
study data, n
1687 1637
Age, mean (SD), y 55.5 (10.9) 56.7 (10.9)
Current tobacco user, n (%) 124 (7.4) 127 (7.8)
Current alcohol user, n (%) 114 (6.8) 120 (7.3)
Physically inactive, n (%) 1078 (63.9) 937 (57.2)
Height, mean (SD), cm 159.0 (9.3) 157.8 (9.1)
Weight, mean (SD), kg 65.6 (11.9) 65.1 (12.2)
Body mass index, mean (SD), kg/m2 26.0 (4.6) 26.2 (4.6)
SBP, mean (SD), mm Hg* 138.6 (17.0) 136.6 (18.4)
Diastolic blood pressure, mean (SD), 
mm Hg*
83.8 (10.9) 82.3 (11.4)
Fasting blood glucose, mean (SD), 
mg/dL†‡
148.7 (67.9) 150.9 (66.8)
HbA1c, mean (SD), %† 7.5 (2.4) 7.6 (2.3)
Total cholesterol, mean (SD), mg/dL 194.7 (45.2) 193.8 (45.2)
CVD risk score, mean (SD), % 41.5 (21.5) 41.0 (21.1)
CVD indicates cardiovascular disease; EUC, enhanced usual care; HbA1c, 
glycated hemoglobin; and SBP, systolic blood pressure.
*Participants with hypertension.
†Participants with diabetes mellitus.
‡Using capillary blood.
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(57.9% versus 81.1%) and antihyperglycemic (68.9 
versus 82.4%) medications. During the trial period, 
there was no difference in drug availability between 
the arms. Among antihypertensive drugs, β-blockers 
and calcium channel blockers were more frequently 
available than angiotensin-converting enzyme in-
hibitors/angiotensin receptor blockers or diuretics. 
Among antihyperglycemic drugs, metformin was 
available 78.2% and 82.9% of the time whereas sul-
fonylureas were available only 42.9% and 45.6% of 
the time in the mWellcare and EUC arms, respectively. 
Overall, a high proportion of physicians accepted DSR 
prompts for hypertension and diabetes mellitus (68% 
and 69%, respectively). The most common cause for 
nonacceptance of the DSR was nonavailability of the 
EDS-recommended drugs at the CHC. Participants 
overwhelmingly noted improvement in the quality of 
care in both EUC and mWellcare CHCs (96.6% and 
95.0%, respectively).
DISCUSSION
This cluster-randomized trial using hypertension and 
diabetes mellitus as entry points evaluated the effec-
tiveness of mWellcare, an mHealth-based EDS, in the 
integrated management of hypertension and diabe-
tes mellitus with comorbid conditions (depression and 
tobacco and alcohol use) in 40 CHCs in India for 12 
months. The trial did not find any statistically signifi-
cant difference in the prespecified primary outcomes of 
reduction in SBP or HbA1c between the 2 arms. Sec-
ondary outcomes such as fasting blood glucose, total 
cholesterol, predicted 10-year risk of CVD, body mass 
index, depression, and tobacco and alcohol use were 
also not significantly different between the 2 arms. The 
primary outcome results were consistent across pre-
specified individual- and CHC-level subgroups despite 
heterogeneity among CHCs. This heterogeneity was 
potentially driven by site-level personnel (NPCDCS-
appointed NCD nurses versus trial fund–supported 
NCD nurses), intervention fidelity, recruitment bias, or 
chance and requires future research. These results were 
also consistent in the sensitivity analyses.
Previous cluster-randomized trials in India evaluating 
EDS-based hypertension management in primary care 
demonstrated substantial reductions in SBP and bet-
ter adherence to therapy, accompanied by significant 
improvement in lifestyle factors such as salt reduction, 
increased physical activity, and higher intake of fruits 
and vegetables.15 The trial by Anchala et al,15 however, 
focused on isolated hypertension management and 
was delivered entirely by physicians. Furthermore, the 
absence of nurse support in the control arm in this tri-
al, compared with our study, may have resulted in the 
Table 3. Primary and Secondary Outcomes at the End of Study
Variable
Mean Change Unadjusted Adjusted*
EUC Arm mWellcare Arm Effect Size (95% CI) P Value Effect Size (95% CI) P Value
Primary outcomes
  Change in SBP, mm Hg† −12.7 −13.7 −1.0 (−4.6 to 2.7) 0.607 −0.3 (−3.9 to 3.3) 0.869
  Change in HbA1c, %‡ −0.58 −0.48 0.11 (−0.24 to 0.45) 0.563 0.08 (−0.27 to 0.44) 0.660
Secondary outcomes
  Fasting blood glucose, mg/dL‡§ −22.7 −15.0 7.7 (−10.3 to 25.6) 0.416 8.4 (−9.6 to 26.5) 0.372
  Total cholesterol, mg/dL‖ 2.0 0.1 −1.8 (−6.3 to 2.7) 0.444 −2.5 (−7.1 to 2.0) 0.292
  CVD risk score, %‖ 0.6 2.4 1.7 (−0.8 to 4.3) 0.196 −0.4 (−2.3 to 1.5) 0.658
  Body mass index, kg/m2‖ 0.08 0.16 0.07 (−0.37 to 0.52) 0.749 −0.05 (−0.47 to 0.37) 0.823
  Change in tobacco use, %‖ −7.0 −6.0 0.9 (−3.2 to 5.0) 0.649 −0.8 (−5.7 to 4.2) 0.756
  Change in alcohol use, %‖ −3.8 −2.4 1.4 (−2.6 to 5.4) 0.480 0.7 (−3.7 to 5.1) 0.741
Variables assessed only at end of study
  Alcohol use score‖ 10.0 9.4 −0.6 (−3.3 to 2.0) 0.642 −0.6 (−3.2 to 2.1) 0.683
  Depression score‖ 12.4 10.9 −1.4 (−4.2 to 1.4) 0.335 −1.6 (−4.4 to 1.2) 0.276
CVD indicates cardiovascular disease; HbA1c, glycated hemoglobin; and SBP, systolic blood pressure.
*For SBP, we adjusted for education, lipid-lowering drugs, aspirin use, peripheral vascular disease, and smoking status; for HbA1c, we adjusted for age, 
employed, antihyperglycemic drugs, peripheral vascular disease, and alcohol use; for fasting blood glucose, we adjusted for diabetes medication and 
peripheral vascular disease;  total cholesterol was adjusted by height, employment, blood pressure medication, smoking, alcohol drinking and physical 
activity; for risk score, we adjusted for age, employment, blood pressure medication and smoking; for BMI, we adjusted for height, sex, marital status, 
education, employment, blood pressure medication, diabetes medication, lipid lowering medication, physical activity, smoking and alcohol; for change in 
tobacco and alcohol use, we adjusted for their own baseline values, age, sex, marital status, education and employment;  for alcohol use and depression 
scores, we adjusted for age, sex, baseline alcohol and education.
†n indicates participants with hypertension.
‡n indicates participants with diabetes mellitus.
§Using capillary blood.
‖n indicates all participants.D
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observed large difference between the 2 arms. Several 
systematic reviews and meta-analyses on the effective-
ness of EDS report inconsistent and variable results 
(weak to modest positive results) for mean change in 
CVD risk factors such as SBP and diastolic blood pres-
sure, total and low-density lipoprotein cholesterol, and 
HbA1c.
12,13,34–36
Several factors at the health system, care provider, 
and patient levels may have influenced the trial null 
results such as variations in the health system. These 
include infrastructural resources; leadership by the 
medical officer in charge; competing demands on the 
healthcare provider (the wide spectrum of diseases 
handled by a single CHC physician); NCD nurses as-
signed to do other duties, including immunizations and 
emergencies; and patient-level barriers (poor follow-up 
rates). Major factors that might have influenced the 
trial null results are described next.
First, the presence of NCD nurses in both the EUC 
and mWellcare arms could have influenced the results. 
NCD nurses in the EUC arm proactively maintained a 
separate register for the trial patients and provided spe-
cial attention to trial participants in terms of scheduling 
follow-up visits and counseling on self-management, 
adherence to medications, and regular monitoring of 
blood pressure and glucose levels. This is reflected in 
the marked improvement in the quality of care report-
ed in the EUC arm as in the mWellcare arm. A large tri-
al from India (the CARRS trial) demonstrated a benefi-
cial role of a nonphysician care coordinator enabled by 
EDS at tertiary care centers in improving the composite 
of HbA
1c, blood pressure, and low-density lipoprotein 
cholesterol. In contrast to our trial, the CARRS trial did 
not have a separate nonphysician care coordinator in 
the control group.14 Second, the centralized training 
provided to the physicians and NCD nurses on hyper-
tension and diabetes mellitus management could have 
improved the knowledge of care providers, translating 
to better quality of care in both arms, and diluted the 
benefit of EDS. Third, charts on treatment algorithms 
were also provided in clinics for physicians in the EUC 
arm, which could have influenced the findings. Fourth, 
the research team advocated for the availability of es-
sential drugs for hypertension and diabetes mellitus 
management in all the participating CHCs, which is 
otherwise poor and inconsistently available.16 The 
fortnightly visit by trial monitors for the process data 
collection, particularly drug availability, may have influ-
Figure 2. Primary outcome: systolic blood 
pressure (SBP) by prespecified baseline 
subgroups. 
HTN indicates hypertension; NPCDCS, National 
Program for the Prevention and Control of 
Cancer, Diabetes, Cardiovascular Diseases and 
Stroke; and Pval-Het, P value–heterogeneity. 
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enced the behavior of staff in ensuring the availability 
of drugs in the CHCs in both arms. Fifth, the Haw-
thorne effect, that is, behavioral change among care 
providers resulting from the open-label nature of the 
cluster-randomized trial, could have influenced better 
care delivery in the EUC arm, leading to null results. 
Process evaluation has documented that both arms 
had improvement in care delivery, drug availability, per-
ceived quality of care by patients, and satisfaction of 
physicians in getting assistance from NCD nurses. Last-
ly, the mWellcare arm, compared with the EUC arm, 
had higher self-reported adherence to medication that 
did not translate into clinical benefits. Potential bias 
in self-reporting may have played a role; however, an 
absence of clinical benefit despite higher medication 
adherence has been observed in similar trials.37,38
Implications of Study Findings on India’s 
National NCD Control Program
Although we found a null result, the trial demonstrated 
large reductions in blood pressure and HbA1c in both 
arms. The reductions in blood pressure levels in both 
arms were comparable with the mPower Heart study, 
a pre-post evaluation of EDS-facilitated nurse-delivered 
intervention in Himachal Pradesh.16 The role of nurses 
in the NCD clinics and the availability of drugs appear 
to have played crucial roles in improving outcomes. 
Furthermore, the trial facilitated a systematic patient 
assessment and guideline-based management and 
follow-up of patients with hypertension and diabetes 
mellitus. In addition, the training of physicians and 
NCD nurses (which is not otherwise part of usual care 
in India) may have contributed to the better quality of 
care. The government of India recently launched the 
ambitious Ayushman Bharat program, which aims to 
create 150 000 health and wellness centers to provide 
comprehensive primary health care, with a strong focus 
on prevention and management of NCDs through the 
provision of screening, follow-up, essential drugs, and 
diagnostic services facilitated by nonphysician care pro-
viders.39 Thus, this trial supports the approach of the 
national program in terms of making provision for an 
NCD nurse for optimal management of chronic condi-
tions. Additional components that need to be empha-
sized are the training of physicians and NCD nurses and 
ensuring a continuous and adequate drug supply. This 
trial also demonstrated the feasibility of incorporating 
Figure 3. Primary outcome: glycohemo-
globin (HbA1c) by prespecified baseline 
subgroups. 
HTN indicates hypertension; NPCDCS, National 
Program for the Prevention and Control of 
Cancer, Diabetes, Cardiovascular Diseases and 
Stroke; and Pval-Het, P value–heterogeneity.
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EDS and electronic storage of health records for NCD 
management in primary care. The government of India 
is preparing to roll out an electronic health record sys-
tem in the public health system. This study can inform 
policymakers while that countrywide program is rolled 
out in India.
Strengths and Limitations
A major strength of this trial is that it tested an integrat-
ed strategy of managing 5 common chronic conditions 
with hypertension and diabetes mellitus used as entry 
points in a well-designed cluster-randomized controlled 
trial with adequate power. As far as possible, the trial 
mimicked a typical primary care healthcare system in In-
dia. Several system-level improvements were mandated 
as part of the trial, and robust process outcomes were 
carried out. Sophisticated statistical analysis to account 
for regression to the mean was performed.
Although this trial had null results, we demonstrated 
other benefits of using an mHealth system for NCD 
management. These benefits include generating an 
electronic patient registry, monitoring quality of care, 
centrally updating clinical protocols for all users through 
the mHealth application, and generating useful infor-
mation from the registry for planning (eg, forecasting 
requirement of drugs, diagnostics, manpower).
However, we recognize some relevant limitations. Be-
cause of the trial’s cluster design, we were unable to blind 
the healthcare team and participants. Furthermore, it was 
difficult to blind independent assessors who carried out 
the end-of-study evaluations. In addition, the enhance-
ments in the EUC arm to make it comparable to the 
mWellcare arm could have affected the effect size sub-
stantially. Many cluster-randomized trials evaluating sys-
tem-level quality interventions for CVD care have shown 
mostly null results.40,41 A major reason for this outcome 
has been lack of power; however, our study had ade-
quate power, and thus, the null result is truly informative.
Conclusions
We did not find an incremental benefit of mWellcare 
over EUC in the management of the chronic conditions 
studied. However, this study has important lessons for 
health systems in terms of the management of NCDs in 
primary care settings. The most important lessons are 
providing a clinic nurse to support the physician in the 
management of hypertension and diabetes mellitus, 
ensuring continuous availability of essential drugs, and 
periodic training of healthcare professionals on guide-
line-directed care.
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